We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Effect of Rotigotine Extended-Release Microspheres Alone or With Celecoxib on the Inflammatory Pain.
- Authors
Li, Keke; Zhang, Yijia; Tian, Enming; Liu, Zikai; Wang, Tian; Fu, Fenghua
- Abstract
Clinical trials of rotigotine extended-release microspheres (RTGT-MS), which provides a sustained release of rotigotine for near 2 weeks in vivo , have been conducted in the treatment of Parkinson's disease (PD). This study was to investigate the analgesic effect of RTGT-MS, and to know whether RTGT-MS have synergistic interaction with non-steroidal anti-inflammatory drug, celecoxib. The inflammatory pain model of rats was prepared by carrageenan-induced paw edema. The thermal and mechanical stimuli were applied and the hindpaw withdrawal latency (HWL) response was evaluated. Treatment with RTGT-MS increased the HWL in a dose-dependent manner. The ED50 of RTGT-MS was 24.68 ± 1.02 mg/kg. Isobolographic analysis shows that the combination of RTGT-MS and celecoxib resulted in a synergistic antinociceptive effect. Further results demonstrated that antinociceptive effect of RTGT-MS was accompanied with that PKA, cAMP, COX-2, and PGE2 levels were decreased. Chlorpromazine, a dopamine receptor blocker, not only weakened the analgesic effect of RTGT-MS, but also increased the levels of cAMP, PKA, COX-2, and PGE2. These findings provide a rationale for the combination of RTGT-MS and celecoxib in the treatment of PD, which may reduce the dose of celecoxib, thereby lowering the incidence of adverse effects and improving the pain management in PD patients.
- Subjects
CELECOXIB; CARRAGEENANS; MICROSPHERES; PARKINSON'S disease; PAIN management; CYCLOOXYGENASE 2; DOPAMINE receptors; NOCICEPTIVE pain
- Publication
Frontiers in Pharmacology, 2020, Vol 11, pN.PAG
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2020.594387